SkinBioTherapeutics (GB:SBTX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
SkinBioTherapeutics plc has achieved remarkable growth through strategic acquisitions and expanding its product lineup, resulting in a projected turnover of £6.3 million for FY25. The company has successfully extended its Croda partnership and launched new products in Europe, bolstering its presence in the skin health market. With these developments, SkinBioTherapeutics anticipates becoming cash flow positive by FY25, minimizing the need for further fundraising.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
